Therapeutic Response

MSI-H status confers therapeutic sensitivity to Ipilimumab in combination with Nivolumab in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Opdivo (nivolumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.
Opdivo (nivolumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: first-line treatment of unresectable or metastatic colorectal cancer; treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.
Yervoy (ipilimumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.
Yervoy (ipilimumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.
Opdivo (nivolumab) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Yervoy (ipilimumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.
Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab for reimbursement as a treatment option for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.
Nivolumab 240 mg and Ipilimumab 1mg/kg Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab as a treatment option for the first-line treatment of adult patient with unresectable or metastatic mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).